Results 101 to 110 of about 26,165 (195)
Malaria Journal, 2009 Background Mefloquine and artesunate combination therapy is the recommended first-line treatment for uncomplicated malaria throughout much of south-east Asia. Concerns have been raised about the potential central nervous system (CNS) effects of both drug
Singhasivanon Pratap +9 more
doaj +1 more source
Costing Artemisinin-based Combination Therapy for Malaria in Tanzania [PDF]
, 2005 Malaria continues to be a major contributor to the burden of disease in Tanzania, with a prevalence of 33.39 percent nationally. As antimalarial resistance to sulfadoxine-pyrimethamine in Tanzania continues to grow, the government is in the process of ...
Derriennic, Yann, Wolf, Katherine
core
, 2015 Antimalarial drugs are a powerful tool for malaria control and elimination. Artemisinin-based combination therapies (ACTs) can reduce transmission when widely distributed in a campaign setting.
Eckhoff, Philip +2 more
core +1 more source
Dose-Response, 2015 India is one of the endemic areas where control of malaria has become a formidable task. Artesunate is the current antimalarial drug used to treat malaria, especially chloroquine resistant.
Ketaki R. Desai +3 more
doaj +1 more source
Developing Ontology Support for Human Malaria Control Initiatives [PDF]
, 2011 Malaria is one of the most common infectious diseases and an enormous public health problem in Sub-Sahara Africa, Asia and parts of America. In this paper, we discuss the development of the Human Malaria Control Ontology (HMCO) which contains ...
Daramola, Olawande, Fatumo, S.
core
HeliyonDiffuse Large B-cell lymphoma (DLBCL) is a highly aggressive disease with heterogeneous outcomes and marked variability in the response to chemotherapy. DLBCL comprises two major subtypes: germinal centre B-cell-like (GCB) and activated B-cell-like (ABC).
Dan Xiong +7 more
doaj +1 more source
Efficacy and Safety of Mefloquine, Artesunate, Mefloquine-Artesunate, and Praziquantel against Schistosoma haematobium: Randomized, Exploratory Open-Label Trial [PDF]
, 2017 Background. Morbidity control of schistosomiasis relies on a single drug, praziquantel. The antimalarial drug mefloquine possesses interesting antischistosomal properties, yet no clinical studies have been performed. Methods.
Adoubryn, Koffi D. +7 more
core
Malaria vaccines 1985-2005: a full circle?
, 2005 Few who were actively engaged in malaria vaccine research 20 years ago (including myself) would have imagined that, in 2005, there would still be a prediction of a 10-20-year horizon before vaccines become part of malaria-control strategies.
Targett, Geoffrey A
core +1 more source
Post‐Artesunate Delayed Hemolysis: Anything That Can Go Wrong Will Go Wrong—Murphy's Law
Clinical Case ReportsIn patients presenting with post‐malarial anemia following intravenous artesunate treatment, post‐artesunate delayed hemolysis should be considered in the differential diagnosis, even in endemic settings.
Beliza Chemutai +6 more
doaj +1 more source
Role of GRP78 inhibiting artesunate-induced ferroptosis in KRAS mutant pancreatic cancer cells
Drug Design, Development and Therapy, 2019 Kang Wang,1,* Zhengyang Zhang,1,* Ming Wang,1 Xiongfeng Cao,1 Jianchen Qi,1 Dongqing Wang,1,2 Aihua Gong,3 Haitao Zhu1,21Central Laboratory of Medical Imaging, Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, People’s ...
Wang K +7 more
doaj